Abstract: In December 2019 SARS-CoV-2 initiated a worldwide COVID-19 pandemic, which is still ongoing in 2022. Although adult elderly patients with chronic preexisting diseases had been identified as the most vulnerable group, COVID-19 has also had a significant impact on pediatric intensive care. Early in 2020, a new disease presentation, multisystemic inflammatory syndrome, was described in children. Despite the vaccination that is available for all age categories, due to its selection process, new viral mutations and highly variable vaccination rate, COVID-19 remains a significant clinical challenge in adult and pediatric intensive care in 2022.

Keywords: SARS-CoV-2; COVID-19; pediatric; child; management; intensive care

1. Introduction

Since December 2019, the SARS-CoV-2 virus has had a significant impact on healthcare systems all over the world, with over 3.8 million directly associated deaths being reported [1]. Due to this rapid worldwide disease spread and hospital overload, the World Health Organization (WHO) announced a global pandemic situation on 11 March 2020 [2]. The SARS-CoV-2 infection/disease—Coronavirus Virus Disease 2019 (COVID-19) was recognized and included in the International Classification of Diseases and Related Health Problems (ICD-11) under the code XN109. As in previous coronavirus epidemics (SARS-1, MERS), the primary symptoms of COVID-19 were respiratory, related to viral pneumonia and subsequent acute respiratory distress syndrome (ARDS), which was responsible for most COVID-19-related deaths. Although the disease was initially reported as being most dangerous and fatal predominantly in the elderly population (over 60 years) with major comorbidities [3], a specific pediatric-related presentation of SARS-CoV-2 infection has been described, based on the multisystemic inflammatory syndrome (Pediatric Inflammatory Multisystem Syndrome Temporally associated with COVID-19-PIMS-TS) [4]. Extraordinary research activities throughout the whole scientific community, with the aim of slowing down the pandemic as soon as possible, resulted in a unique situation in human history, as the first vaccine against SARS-CoV-2 was presented approximately one year after the first COVID-19-reported infection. Unprecedented progress has also been made in the in the treatment strategy (from Remdesivir, to corticosteroids, monoclonal antibodies and direct antivirics against SARS-CoV-2); moreover, numerous recommendations for COVID-19 and PIMS-TS have been published since 2019. Despite the vaccination being available for all age categories, due to the selection process, as well as due to the new viral mutations
and highly variable vaccination rate, COVID-19 remains a significant clinical challenge in adult and pediatric intensive care in 2022. This review aims to summarize the current evidence-based data considering the COVID-19 and PIMS-TS, and to be applicable in pediatric intensive-care settings.

2. SARS-CoV-2 Basic Information

 Coronaviruses have been recognized as primary zoonotic RNA single-strand encapsulated viruses (with viral envelope), that can cause mild, dominantly respiratory infection in humans. The first severe acute respiratory syndrome coronavirus (SARS-CoV) epidemic in 2002 and, subsequently, the second epidemic caused by the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, raised deep concerns regarding possible future coronavirus outbreak in the scientific communities worldwide [5]. The concerns were primarily based on its high transmissibility, severity of clinical presentation, lack of possible antiviral treatment and high lethality (15% in SARS vs. 37% in MERS) [6]. After the first published case reports/case series in December 2019, in Wuhan, China, the novel Beta-coronavirus was described as SARS-CoV-2 causing atypical severe pneumonia and ARDS with high reported mortality. Its outbreak launched the world SARS-CoV-2 pandemic in 2020 [3,7,8]. SARS-CoV-2 shares 79% of its genetic information with SARS-CoV-1 and 50% with MERS-CoV [9], and most likely originated from bats or pangolins [5,10]. The virus can spread by close contact (hands, eyes, nose, mouth) and airborne transmission [10]. The virus spike (S) protein binds to the angiotensin-converting enzyme II (ACE2) receptor, expressed on the surface of several tissues (alveolar type II cells in the lungs, myocardial cells, esophageal, ileocolic cells) [2,11,12]. Rapid viral replication in the lungs can lead to pathophysiological damage on the lung tissue (bilateral diffused alveolar damage, hyaline membrane formation, desquamation of pneumocytes and fibrin deposits–primary ARDS) and/or trigger a massive immune response and create a cytokine storm, with many possible clinical features (secondary ARDS, sepsis, septic shock, multiorgan system failure (MOF), multiorgan system dysfunction (MODS)) [5,13–15]. Due to the rapid and widespread SARS-CoV-2 outbreak in the human population and the worldwide spread of the virus, there has been high selection potential for possible, more contagious strains (e.g., the recently dominant Omicron variant). For epidemiologic and virologic purposes, several nomenclatures have been adopted (Pango lineage, GISAID clade, Nextstrain clade) to describe so-called SARS-CoV-2 variants of concern (VOC), with increased transmissibility, virulence, severe clinical presentation and/or with decreased potential for available treatment options [16]. The most prevalent variants are listed in Table 1. The most virulent and worldwide variant, which was prevalent at the beginning of the year 2022, has been the Omicron variant.

Table 1. Currently designated variants of concern (VOCs)+ by WHO.

| WHO Label | Pango Lineage | Earliest Documented Samples | Date of Designation |
|-----------|--------------|-----------------------------|---------------------|
| Alpha     | B.1.1.7      | United Kingdom, September 2020 | 18 December 2020 |
| Beta      | B.1.351      | South Africa, May 2020       | 18 December 2020 |
| Gamma     | P.1          | Brazil, November 2020        | 11 January 2021    |
| Delta     | B.1.617.2    | India, October 2020          | VOC: 11 May 2021   |
| Omicron   | B.1.1.529    | Multiple countries, November 2021 | VOC: 26 November 2021 |

Adapted from: World Health Organization [16].

3. COVID-19 Clinical Presentation and Risk Factors

 COVID-19’s clinical presentation can vary significantly, from asymptomatic infection, mild respiratory symptoms (flu-like disease), to severe or even critical infection (hypoxemia, shock, ARDS, multiple organ failure), as in Table 2 [10,17,18]. The most prevalent clinical COVID-19-related symptoms in children are cough, myalgia, fatigue, sore throat, dyspnea, hypoxemia, fever, gastrointestinal symptoms (diarrhea, nausea and vomiting, abdominal
discomfort), anosmia, ageusia and multisystemic inflammation syndrome [10,17,18]. The onset of clinical symptoms can also vary (high interindividual variability, possible variability in correspondence with the viral load and viral mutation) between 1 and 14 days from transmission [10,19].

Table 2. COVID-19 clinical presentation.

| Clinical Presentation       | Description                                                                 |
|-----------------------------|-----------------------------------------------------------------------------|
| Asymptomatic infection      | No clinical or radiological signs of COVID-19, positive PCR or antigen test |
| Mild infection              | Upper respiratory tract infection symptoms—fever; flu-like symptoms—myalgia, joint pain, fever, cough, sneezing, running nose, abdominal discomfort/pain, anosmia, ageusia, no radiological signs of disease |
| Moderate infection          | Upper and lower respiratory tract infection signs with possible wheezing, crackles, dyspnea with oxygen saturation < 94% on air, radiological signs of disease (X-ray or computed tomography) without other vital signs of deterioration |
| Severe infection            | Dyspnea, tachypnea, hypoxemia (oxygen saturation < 94% on air) + radiological findings (in over 50% of lung tissue) |
| Critical infection          | ARDS, encephalopathy, coagulopathy, acute renal failure, heart failure, shock, multiorgan failure + radiological findings |

Adapted from: [10,18].

The identified risk factors for a severe course of COVID-19 are age (over 60 years and below 1 year), obesity, hypertension, pulmonary disease (e.g., COPD, asthma bronchiale), preexisting organ dysfunction, immunosuppression, oncology disease in the acute phase of treatment, vaccination status of the patient (with higher probability of severe course in those who are unvaccinated or have incomplete vaccination) [16,18].

4. Pediatric Population

Most children (up to 45%) infected with SARS-CoV-2 were asymptomatic or presented with mild upper respiratory tract infection symptoms (over 35%) according to previously published observational data [20,21]. The gastrointestinal symptoms were more prevalent in pediatric patients with COVID-19 compared to adults [22–24]. Another specific clinical presentation with multisystemic inflammation, shock, fever and organ failure was described in children exposed to SARS-CoV-2 as pediatric inflammatory multisystemic syndrome temporally associated with COVID-19 (PIMS) in the United Kingdom (Royal College of Pediatrics and Child Health) or as multisystemic inflammatory syndrome in children (MIS-C) in the US and Europe (Centers for Disease Control and Prevention and European Centre for Disease Control and Prevention) [25–27]. The pathophysiology of PIMS-TS is not yet well described. It remains unknown whether it represents a dysregulated immune response to COVID-19 infection or a new SARS-CoV-2-related childhood disease. [28–30]. Due to its unique clinical presentation and specific treatment algorithm, the PIMS-TS will be described in this review in more detail.

The clinical course of COVID-19 in children, in general, is less severe than in adults. The recognized risk factor for severe complications and the need for hospital admission in children is age under 2 years [21,31–34]. Other identified risk factors for severe COVID-19 in children were obesity, chronic medical condition (e.g., diabetes mellitus, hypertension), chronic pulmonary disease, neurologic and development disorders, prematurity, age < 1 year, age < 1 month [31,32,34]. The overall reported COVID-19 mortality rate in children is below 0.2%, with in-hospital mortality between 0.1 and 8% [34–36].

5. Diagnostic Methods and Laboratory and Imaging Findings

The gold standard for SARS-CoV-2 detection is the viral nucleic acid findings by the real-time reverse transcriptase-polymerase chain reaction (RT-PCR) from the biospeci-
men obtained from the patient’s upper or lower airway mucosal samples (nasopharynx, oropharyngeal swab, tracheal aspirate, bronchoalveolar lavage) [10]. Furthermore, the viral particles can also be found in stool, urine or blood samples [37]. The nature of the PCR method can also reveal the nonviable RNA viral parts (with no invasive and replication potential). Although PCR is considered the gold standard for SARS-CoV-2 detection accepted worldwide, a positive PCR test in an asymptomatic patient does not necessarily mean active COVID-19 disease. However, due to a possible delay of up to 5 days between the initial viral exposure and positive PCR detection, one negative RT-PCR test should not exclude the possibility of COVID-19 in symptomatic patients with a high likelihood of SARS-CoV-2 infection (the testing should be repeated 1–5 days after the initial negative result) [38,39]. Rapid antigen testing from nasopharynx, oropharynx, nasal cavity or even saliva represents a relatively cheap and fast testing option, with a lower sensitivity but high specificity. Although it is possible to use antigen testing for the screening of asymptomatic patients (low time and resource requirements), their performance is best in symptomatic patients with a high viral load (early stages of COVID-19) [38]. Serologic (antibodies) testing for COVID-19 activity or to determine the immunity against SARS-CoV-2 is not recommended [38].

Laboratory findings in COVID-19 could reveal elevated inflammatory markers—C-reactive protein (CRP), procalcitonin, and interleukin-6 with normal or even reduced white blood cell count (leukopenia and/or lymphopenia) [10,38]. Other laboratory abnormalities that could be found in COVID-19 are elevated lactate dehydrogenase and transaminase levels, elevated D-dimers and ferritin [38]. Organ-specific laboratory findings (troponin, brain natriuretic peptide, creatinine, etc.) can be found in cases of severe or even critical course of the disease with organ failure.

Chest X-ray or even computed tomography (CT) of the lungs in from moderate to critical COVID-19 can reveal diffuse lung tissue infiltration (pneumonia) with ground glass opacities and areas of lung consolidation (ARDS findings on CT) [38]. Lung ultrasound can reveal so-called interstitial lung syndrome with signs of lung tissue infiltration (cumulation of the vertical B-lines and diminished horizontal A lines), together with the areas of lung consolidation and “hepatization” (not aerated lung tissue) [40].

6. Initial Approach

Personnel safety issues should be considered the primary mainstay of care of a critically ill pediatric patient with COVID-19. Personal protective equipment (PPE) should be used prophylactically in all patients during the pandemic with possible COVID-19 (until proven noninfectious). The recommended PPEs are FFP2/FFP3/N95 masks, surgical mask, face shield, goggles, surgical gloves and protective gown. Ideally, the intensive care unit for COVID-19-positive patients should be separated from non-COVID-19 care.

The initial assessment of the critically ill pediatric patient should be standardized according to local or international protocols. One of the possible approaches is the ABCDE initial approach recommended by the European Resuscitation Council (ERC) and European Paediatric Advanced Life Support taskforce (EPALS), as in Table 3 [41,42].

The primary aim of intensive care is to equalize the oxygen delivery to meet the oxygen demands, and, if possible, to normalize the oxygen requirements. The initial management using the ABCDE approach should involve the following:

6.1. Airway and Breathing (A+B)

Use supplemental oxygen with nasal cannula or prongs (up to 2–3 L/min), face mask with reservoir (up to 15 L/min) or high-flow nasal cannula (up to 30 L/min and 100% O2) or non-invasive ventilation (NIV) to avoid hypoxemia (oxygen saturation < 90%) and/or respiratory acidosis [2]. Secure the airway if unable to protect, or invasive ventilation is needed. The cuffed tracheal tubes are recommended for all pediatric patients (improved seal, minimizing the possible viral spread). Secure the airway with rapid sequence induction algorithm by the most skilled operator on the scene with the videolaryngoscope (if
available) [41,43]. Use protective mechanical ventilation if possible: tidal volume ≤ 6 mL/kg, limit the plateau pressure, individualize the positive end-expiratory pressure over the lower inflection point of the compliance curve, prone position if inspired oxygen > 60%. [2,44]. Veno-venous extracorporeal membrane oxygenation (V-V ECMO) is indicated for patients with refractory hypoxemia (veno-arterial ECMO when combined with heart failure). High-frequency oscillatory ventilation (HFOV) should only be used as a rescue strategy [2,44].

Table 3. Recommended initial approach to patients at emergency.

| ABCDE Approach | Aim | Action/Management |
|----------------|-----|-------------------|
| A—Airway | Airway patency, cervical spine protection if indicated | Open the mouth, bend the head (over 1 year), use airway if needed, MILS **, cervical collar or head blocks |
| B—Breathing | Spontaneous breathing efficacy, normoxemia, normocapnia | Pulse oximetry, oxygen, mechanical ventilation if indicated, capnography and blood gases analysis |
| C—Circulation | Oxygen delivery to meet the demand, blood pressure (50–95% according to age), adequate heart rate, capillary refill time ≤ 2 s, lactate ≤ 2 mmol/L | Fluid resuscitation (10 mL/kg fluid challenge), vasopressors or antihypertensives to meet target blood pressure |
| D—Disability | GCS ≥ 9, seizures control | Tracheal intubation and mechanical ventilation if GCS ≤ 8 and anticonvulsants |
| E—Exposure/Examination | Clinical examination, temperature management, normoglycemia (6–10 mmol/L) | Insulin or glucose to meet target glycemia, normothermia |

* ERC (European Resuscitation Council); EPALS (European Paediatric Advanced Life Support). ** Manual in-line stabilization (of the cervical spine). ABCDE—universal initial approach to the patient, considering the importance of vital signs in alphabetical order. GCS—Glasgow coma scale.

6.2. Circulation (C)

The aim is to reach adequate cardiac output and meet the metabolic requirements. In patients with hypotension (according to age), 10 mL/kg balanced isotonic crystalloid in bolus form is recommended for optimizing the cardiac output. This can be repeated up to 40 mL/kg in the first hour, but the effect of treatment needs to be evaluated by echocardiography, or dynamic hemodynamic variables and indirectly by lactate level clearance (to normalize the lactate ≤ 2 mmol/L), capillary refill time (≤ 2 s) and mean arterial blood pressure/perfusion pressure. [2,41,45,46]. In severe hypotension, or if hypotension persists despite adequate fluid resuscitation, norepinephrine or epinephrine infusion should be initiated to normalize the above-mentioned hemodynamic parameters. The ideal route of administration is via the central vein, but the peripheral vein could be temporarily used as well. In persistent hypotension and/or high-catecholamine requirements, hydrocortisone stress dose infusion (4 mg/kg/day) and vasopressin therapy should be initiated [2,41,45,46]. In the case of ARDS, fluid-restrictive therapy is recommended.

6.3. Disability (D)

The ideal neurologic state of the patient in intensive care is alert, calm, without discomfort with satisfactory analgesia, and able to cooperate and communicate with the pediatric intensive care unit (PICU) staff [47]. As defined by the Richmond agitation and sedation scale (RASS), which has recently been validated for pediatric patients, level
0 to −2 (alert to light sedation) is desirable. This could be reached with α-2 agonists (e.g., dexmedetomidine or clonidine) [47,48]. However, in case of shock and/or severe respiratory distress, the only possible initial option could be deep sedation and mechanical ventilation until organ stabilization is achieved.

6.4. Exposure/Examination
Clinical examination, microbiology screening, broad-spectrum antibiotics therapy (until bacterial infection has been ruled out) and radiography examination (X-ray in all patients with possible COVID-19, CT in selected cases with severe to critical presentation) should be part of the standardized care in PICU. Echocardiography, together with cardiac enzymes and cardiology consultation, should be considered in patients with signs of shock, heart and/or multiorgan failure.

7. Antiviral Treatment and Immunotherapy
7.1. Remdesivir
Remdesivir has been approved by the Food and Drug Administration (FDA) for COVID-19 treatment in hospitalized adults and children (≥12 years of age and ≥40 kg of weight). It could also be considered in younger children (<12 years of age and ≥3.5 kg of weight) with a high risk of disease progression, present risk factors for severe disease and in children with rapid disease progression and increasing need for oxygen [38,49]. It is indicated in patients with the need for oxygen therapy and should be administered as soon as possible (within 7 days from the first COVID-19 symptoms), but not in patients who are already on mechanical ventilation.

7.2. Dexamethasone
Dexamethasone is indicated in all hospitalized children and adults with the need for oxygen therapy and/or mechanical ventilation with a dose of 0.15 mg/kg/day (maximum 6 mg/dose) for up to 10 days [38,50].

7.3. Tocilizumab
Tocilizumab is a recombinant monoclonal antibody against the interleukin-6 receptor (originally approved for rheumatoid arthritis treatment). [18,33,51]. Although mainly based on adult EBM data, it can be considered in pediatric patients with rapid disease progression and the need for oxygen therapy within 3 days of hospital admission and within 24 h after PICU admission (including patients on mechanical ventilation) [18,33].

Monoclonal antibodies (anti-SARS-CoV-2 drugs)—bamlanivimab + etesevimab, casirivimab + imdevimab
These monoclonal antibodies could be considered for high-risk pediatric patients that do not require oxygen therapy (≥12 years of age and ≥40 kg of weight) but, due to insufficient evidence, are only suitable for individual consideration [18,33]. However, their effectiveness against omicron variant is questionable.

Convalescent plasma, ivermectin, baricitinib, sarilumab, chloroquine/hydroxychloroquine, Isoprinosine, umifenovir are not recommended for COVID-19 treatment in pediatric patients.

8. Supportive Intensive Care
Besides the standard supportive care, such as glycemia control (between 6–10 mmol/L), early enteral nutrition, and stress ulcer prophylaxis in high-risk patients [45], venous thromboembolism (VTE) prophylaxis could be considered according to the local protocols by low-molecular-weight heparin (LMWH) with an anti-Xa target between 0.3 and 0.5 IU/mL (in high-risk patients, an even higher dose may be administered, based on individual approach and consultation with hematologist) [2,33].
9. PIMS-TS/MIS-C

9.1. Definition

Early in 2020, the specific Kawasaki-like disease was first described, characterized by multisystemic inflammation and signs of organ dysfunction and/or failure presenting only in pediatric patients [4]. When the link to SARS-CoV-2 infection was identified in these patients, the new diagnosis was described as pediatric inflammatory multisystemic syndrome temporally associated with COVID-19 (PIMS-TS) in the United Kingdom (Royal College of Pediatrics and Child Health), or as multisystemic inflammatory syndrome in children (MIS-C) in US and Europe (Centers for Disease Control and Prevention and European Centre for Disease Control and Prevention) [25–27], as in Table 4.

Table 4. PIMS-TS and MIS-C definition.

| Organization | Centers for Disease Control and Prevention USA definition | Royal College of Pediatrics and Child Health definition AND European Centre for Disease Control and Prevention definition | World Health Organization |
|--------------|----------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------------------|
| Country      | United States of America                                 | United Kingdom and Europe                                                                       | Worldwide                   |
| Syndrom/disease name | Multisystemic inflammatory syndrome in children (MIS-C) | Pediatric inflammatory multisystemic syndrome temporally associated with COVID-19 (PIMS-TS) | Multisystemic inflammatory syndrome in children (MIS-C) |
| Age          | <21 years                                                | All children (age not defined)                                                                  | 0–19 years                  |
| Clinical symptoms | Both of the following:                                   | Both of the following:                                                                          | At least 2 of the following: |
|              | 1. Severe illness (hospitalized);                        | 1. Single or multiorgan dysfunction;                                                             | 1. Rash, conjunctivitis, and mucocutaneous inflammation; |
|              | 2. ≥2 organ systems involved                             | 2. Additional features                                                                          | 2. Hypotension or shock;   |
|              |                                                          |                                                                                                 | 3. Cardiac involvement;    |
|              |                                                          |                                                                                                 | 4. Coagulopathy;           |
|              |                                                          |                                                                                                 | 5. Acute GI symptoms       |
| Inflammation | Laboratory evidence of inflammation including, but not limited to, 1 or more of the following: | All 3 of the following:                                                                         | Elevated inflammation     |
|              | 1. ↑CRP;                                                 | 1. Neutrophilia;                                                                                | markers, including any of the following: |
|              | 2. ↑ESR;                                                 | 2. Increased CRP;                                                                               | 1. ↑ESR;                   |
|              | 3. ↑Fibrinogen;                                          | 3. lymphopenia                                                                                  | 2. ↑CRP;                   |
|              | 4. ↑Procalcitonin;                                       |                                                                                                 | 3. ↑Procalcitonin          |
|              | 5. ↑D-dimer;                                             |                                                                                                 |                             |
|              | 6. ↑Ferritin;                                            |                                                                                                 |                             |
|              | 7. ↑LDH;                                                 |                                                                                                 |                             |
|              | 8. ↑IL-6;                                                |                                                                                                 |                             |
|              | 9. Neutrophilia;                                          |                                                                                                 |                             |
|              | 10. Lymphopenia;                                          |                                                                                                 |                             |
|              | 11. Hypoalbuminemia                                      |                                                                                                 |                             |
| Link to SARS–CoV-2 | Current or recent findings of the following: | Positive or negative by PCR                                                                     | Evidence of COVID-19 by the following: |
|              | 1. Positive by PCR;                                      |                                                                                                 | 1. Positive by PCR;        |
|              | 2. Positive by serology;                                 |                                                                                                 | 2. Positive by antigen test; |
|              | 3. Positive by antigen test;                             |                                                                                                 | 3. Positive by serology;   |
|              | 4. COVID-19 exposure within prior 4 weeks                |                                                                                                 | 4. Likely COVID-19 contact |
| Exclusion    | No alternative diagnosis                                 | Other infections                                                                                | No obvious microbial cause |

GI—gastrointestinal, CRP—c-reactive protein, ESR—erythrocyte sedimentation rate, LDH—lactate dehydrogenase, IL-6—interleukin 6. Adapted with permission from John Wiley and Sons [52].

9.2. Clinical Presentation

Due to its multivariable clinical presentation, several PIMS-TS/MIS-C definitions have been published. Most of previously healthy pediatric patients with PIMS-TS will present with persistent fever, signs of multisystemic inflammation, and organ dysfunction.
(cardiac, central nervous system, renal, hepatic, coagulation), with no other explanatory
diagnosis and proven or possible contact with SARS-CoV-2. Three dominant PIMS-TS
clinical phenotypes were proposed for clinical consideration and further treatment de-
cisions: 1. heart failure (left ventricular dysfunction) +/− coronary artery dilatation,
2. distributive/vasoplegic shock +/− coronary artery dilatation, 3. coronary artery dilata-
and/or aneurysm formation [28]. Besides the persistent fever, respiratory infection
signs, abdominal discomfort (nausea, vomiting, mitigating acute abdomen) and cardiac
dysfunction (hypotension, tachycardia, laboratory results, as in Table 4.) could be found in
most PIMS-TS patients. [53–56]. In the majority of patients, PIMS-TS develops between 4
and 6 weeks after COVID-19 infection and most patients have positive anti-SARS-CoV-2
antibodies on serology screening. Only a minority of patients could have PCR-positive
results [4,29,38,57–59]. One of the possible explanations for PIMIS-TS pathophysiology
could be autoantibodies-induced tissue damage [60,61]. Several case reports of a similar
hyperinflammatory syndrome were also published in the adult population [62]. Due to
the variety of clinical manifestations and different diagnostic criteria, with some patients
remaining undiagnosed, the described prevalence of the PIMS-TS widely varies [56].

9.3. Initial Approach

The initial approach to the critically ill child with suspected PIMS-TS/MIS-C is based
on the same ABCDE approach as in COVID-19 patients. The goal of the management is
to restore the physiologic vital signs and, until proven otherwise, to treat the condition as
septic shock (microbiology screening + antibiotics). However, PIMS-TS/MIS-C-specific
treatment should not be delayed (for example, due to waiting for PCR or serology results).
Wide laboratory screening (full blood count, coagulation, inflammatory markers-CPR,
procalcitonin, IL-6, ferritin), together with organ-specific tests (troponin and NT-proBNP),
is recommended, together with chest X-ray, 12-lead ECG, abdominal ultrasound (possible
infection source) and echocardiography in all patients. The vast majority of PIMS-TS
patients have elevated cardiac enzymes and abnormal echocardiography (compromised
systolic function, coronary artery dilatation) and require intensive care admission [38,57].
Variable clinical presentation makes PIMS-TS difficult to diagnose, but, given the fact
that the patient’s outcome is associated with the rapidity of diagnostic process, clinicians
should be strongly aware of possible PIMS-TS in every febrile child with signs of organ
dysfunction [38,63]. Care of PIMS-TS patients should be taken in a multidisciplinary team
involving a pediatrician, intensive care physician, rheumatologist, hematologist, infectious
disease physician and cardiologist.

9.4. Specific Treatment

Supportive intensive care (oxygen therapy, mechanical ventilation, hemodynamic re-
suscitation, etc.) is the mainstay of PIMS-TS treatment [38]. Moderate to critical presentation
requires specific immunomodulatory treatment, partially derived from Kawasaki disease
treatment algorithm [64]. In patients with PIMS-TS and moderate to critical clinical presenta-
tion, treatment with intravenous immunoglobulins (IVIG–2 g/kg) and corticosteroids
(methylprednisolone 1–2 mg/kg) is recommended [52]. This combination has been found to
be superior to single IVIG treatment (shorter ICU stay, cardiac function improvement) [65].
IVIG treatment contains a significant amount of fluid load; therefore, the patient’s cardiac
status should be evaluated before IVIG administration. The initial IVIG dose in patients
with severe cardiac dysfunction and the high risk of fluid overload could be divided into
two doses administered in 12 h intervals, or even postponed until hemodynamic stabiliza-
tion (corticosteroids alone + supportive therapy) [66,67]. The second dose of IVIG could be
considered (24 h after initial infusion) in case of severe clinical course and/or inadequate
response to treatment [66]. Corticosteroids should be administered after sepsis/septic
shock is ruled out, in case of high clinical (or laboratory) suspicion on PIMS-TS, and always
in case of severe PIMS-TS cases with multiple organ dysfunction [66]. The recommended
dose of 1–2 mg/kg methylprednisolone per day could be increased up to 30 mg/kg/day
(1 g maximum per dose) in case of shock, multiple organ involvement and/or high vaso-
pressor requirements [8,66]. Intravenous corticosteroids should be administered for from 3
to 4 days, followed by oral prednisone (in case of clinical improvement) [66]. For severe
PIMS-TS cases with insufficient clinical response to IVIG and/or corticosteroids treatment,
interleukin-1 (IL-1) receptor antagonist–Anakinra could be considered [52,66]. An alterna-
tive treatment in refractory cases could be the interleukin-6 antagonist (Tocilizumab) and
tumor necrosis factor-α antagonist (Infliximab) [29,68]. Antiocoagulation prophylaxis with
low-molecular-weight heparin (LMWH), based on local protocol, should be considered in
all PIMS-TS patients who present with at least one of the following: 5–10 times elevation of
D-dimers, mild-to-moderate ventricular dysfunction, significant ECG rhythm abnormali-
ties and coronary artery dilatation/aneurysm findings [69]. Therapeutic antiocoagulation
is recommended in patients with acute thrombosis, moderate-to-severe ventricular dys-
function, z-score coronary artery dilatation/aneurysm ≥ 10, D-dimer >10× elevation [69].
Due to the possible risk of coronary artery dilatation and aneurysm formation, the aspirin
(3–5 mg/kg/day, up to 81 g/day) treatment is recommended in all PIMS-TS hospitalized
patients without risk of bleeding (platelet count >100,000, normal coagulation tests) for at
least one month [69].

9.5. Outcome

The overall reported outcome of COVID-19 and PIMS-TS in children is significantly
better than in adults. The reported PIMS-TS mortality reached up to 2%, but varies signif-
ically [55,57,58,70] and roughly equals the reported mortality of COVID-19 in children
0.9–2% [71,72] with 1.3% mortality, reported on February 2022 [73].

10. Conclusions

In the past two years of the COVID-19 worldwide pandemic, significant efforts have
been made to slow down and stop the viral spread, from using simple face masks up to
vaccine development. New SARS-CoV-2-associated diseases, such as PIMS-TS, have been
described, and several direct antivirals (remdesivir, molnupiravir, etc.) and supportive
drugs have been developed for COVID-19 and PIMS-TS. The new evidence, translated
into the clinical practice, directly led to reduced morbidity and mortality associated with
SARS-CoV-2. The main principle for a positive outcome is based on the early identifica-
tion of patients at risk (standardized ABCDE approach) and early aggressive treatment.

Despite the incredible progress in the care of COVID-19 and PIMS-TS patients, the
battle is not over yet, as new SARS-CoV-2 variants are still being recognized in 2022
(e.g., subvariant BA.2) and the near future remains unclear, but is hopefully positive. The
most effective preventive measure of a severe course of COVID-19 is vaccination, which is
available for all age categories at present; therefore, among other measures, we should also
focus on striving for the highest possible vaccination coverage of the population worldwide.
References

1. Cascella, M.; Rajnik, M.; Aleem, A.; Dulebohn, S.C.; Di Napoli, R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022.

2. Kache, S.; Chisti, M.J.; Gumbo, F.; Mupere, E.; Zhi, X.; Nallasamy, K.; Nakagawa, S.; Lee, J.H.; Di Nardo, M.; de la Oliva, P.; et al. COVID-19 PICU guidelines: For high-and limited-resource settings. Pediatr. Res. 2020, 88, 705–716. [CrossRef] [PubMed]

3. World Health Organization. Coronavirus Disease 2019 (COVID-19): Situation Report. Available online: http://www.Who.Int/docs/default-source/coronaviruse/situation-reports.2 (accessed on 5 February 2022).

4. Riphagen, S.; Gomez, X.; Gonzalez-Martinez, C.; Wilkinson, N.; Theocharis, P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020, 395, 1607–1608. [CrossRef]

5. Hu, B.; Guo, H.; Zhou, P.; Shi, Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021, 19, 141–154. [CrossRef] [PubMed]

6. Abdelghany, T.M.; Ganash, M.; Bakri, M.M.; Qanash, H.; Al-Rajhi, A.M.H.; Elhussieny, N.I. SARS-CoV-2, the other face to COVID-19. World J. Pediatr. 2020, 16, 538–546. [CrossRef] [PubMed]

7. Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; Wu, Y.; Zhang, L.; Yu, Z.; Fang, M.; et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020, 8, 475–481. [CrossRef]

8. Fernández-Sarmiento, J.; De Souza, D.; Jabornisky, R.; Gonzalez, G.A.; Arias López, M.D.P.; Palacio, G. Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): A narrative review and the viewpoint of the Latin American Society of Pediatric Intensive Care (SLACIP) Sepsis Committee. BMJ Paediatr. Open. 2021, 5, e000894. [CrossRef]

9. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; et al. Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020, 395, 565–574. [CrossRef]

10. Carlotti, A.P.C.P.; Carvalho, W.B.; Johnston, C.; Rodriguez, I.S.; Delgado, A.F. COVID-19 Diagnostic and Management Protocol for Pediatric Patients. Clinics 2020, 75, e1894. [CrossRef]

11. Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273. [CrossRef]

12. Li, S.R.; Tang, Z.J.; Li, Z.H.; Liu, X. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: The target of COVID-19 and SARS-CoV. Eur. J. Clin. Microbiol. Infect. Dis. 2020, 39, 1021–1026. [CrossRef]

13. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [CrossRef]

14. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. HLH Across Speciality Collaboration, UK: COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020, 395, 1033–1043. [CrossRef]

15. Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020, 180, 934–943. [CrossRef] [PubMed]

16. World Health Organization. Tracking SARS-CoV-2 Variants. Available online: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed on 5 February 2022).

17. Stokes, E.K.; Zambraño, L.D.; Anderson, K.N.; Marder, E.P.; Raz, K.M.; El Burai Felix, S.; Tie, Y.; Fullerton, K.E. Coronavirus Disease 2019 Case Surveillance–United States. MMWR Morb. Mortal Wkly. Rep. 2020, 69, 759–765. [CrossRef]

18. Marek, S.; Chrdle, A.; Husa, P.; Beneš, J.; Dlouhy, P.; Infekce.cz. COVID-19 Diagnostika a L.éèba. Available online: https://www.infekce.cz/DPCovid21/DP5-covid-DP-podrobny-09-21.pdf (accessed on 5 February 2022).

19. Chen, Z.M.; Fu, J.F.; Shu, Q.; Chen, Y.H.; Hua, C.Z.; Li, F.B.; Lin, R.; Tang, L.F.; Wang, T.L.; Wang, W.; et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J. Pediatr. 2020, 16, 240–246. [CrossRef] [PubMed]

20. Poline, J.; Gaschignard, J.; Leblanc, C.; Madhi, F.; Foucaud, E.; Nattes, E.; Faye, A.; Bonacorsi, S.; Mariani, P.; Varon, E.; et al. Systematic Severe Acute Respiratory Syndrome Coronavirus 2 Screening at Hospital Admission in Children: A French Prospective Multicenter Study. Clin. Infect. Dis. 2021, 72, 2215–2217. [CrossRef]

21. Dong, Y.; Mo, X.; Hu, Y.; Qi, X.; Jiang, F.; Jiang, Z.; Tong, S. Epidemiology of COVID-19 Among Children in China. Pediatrics 2020, 145, e20200702. [CrossRef]

22. Ogimi, C.; Englund, J.A.; Bradford, M.C.; Qin, X.; Boeckh, M.; Weghmare, A. Characteristics and Outcomes of Coronavirus Infection in Children: The Role of Viral Factors and an Immunocompromised State. J. Pediatr. Infect. Dis. Soc. 2019, 8, 21–28. [CrossRef] [PubMed]

23. Morand, A.; Fabre, A.; Minodier, P.; Boutin, A.; Vanel, N.; Bosdure, E.; Fournier, P.E. COVID-19 virus and children: What do we know? Arch. Pediatr. 2020, 27, 117–118. [CrossRef]

24. Balasubramanian, S.; Rao, N.M.; Goenka, A.; Roderick, M.; Ramanan, A.V. Coronavirus Disease 2019 (COVID-19) in Children-What We Know So Far and What We Do Not. Indian Pediatr. 2020, 57, 433–442. [CrossRef]

25. Royal College of Pediatrics and Child Health. Guidance: Paediatric Multisystem Inflammatory Syndrome Temporally Associated with COVID-19. Available online: https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf (accessed on 5 February 2022).
26. Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). Available online: https://emergency.cdc.gov/han/2020/han00432.asp (accessed on 5 February 2022).

27. European Centre for Disease Prevention and Control. Paediatric Inflammatory Multisystem Syndrome and SARS-CoV-2 Infection in Children. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-risk-assessment-paediatric-inflammatory-multisystemsyndrome-15-May-2020.pdf (accessed on 5 February 2022).

28. Rimensberger, P.C.; Kneyber, M.C.J.; Deep, A.; Bansal, M.; Hoskote, A.; Javouhey, E.; Jourdain, G.; Latten, L.; MacLaren, G.; Morin, L., et al. European Society of Pediatric and Neonatal Intensive Care (ESPNIC) Scientific Sections’ Collaborative Group. Caring for Critically Ill Children with Suspected or Proven Coronavirus Disease 2019 Infection: Recommendations by the Scientific Sections’ Collaborative of the European Society of Pediatric and Neonatal Intensive Care. Pediatr. Crit. Care Med. 2021, 22, 56–67. [CrossRef] [PubMed]

29. Whittaker, E.; Bamford, A.; Kenny, J.; Kafrontou, M.; Jones, E.; Shah, P.; Ramnarayan, P.; Fraisse, E.; Miller, O.; Davies, P., et al. Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporarily Associated With SARS-CoV-2. JAMA 2020, 324, 259–269. [CrossRef] [PubMed]

30. Belot, A.; Antonia, D.; Renolleau, S.; Javouhey, E.; Hentgen, V.; Angoulvant, F.; Delacourt, C.; Iriart, X.; Ovaert, C.; Bader-Meunier, B., et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Euro Surveill. 2020, 25, 2001010. [CrossRef] [PubMed]

31. Swann, O.V.; Holden, K.A.; Turtle, L.; Pollock, L.; Fairfield, C.J.; Drake, T.M.; Seth, S.; Egan, C.; Hardwick, H.E.; Halpin, S., et al. ISARIC4C Investigators. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: Prospective multicentre observational cohort study. BMJ 2020, 370, m3249. [CrossRef]

32. Götzinger, F.; Santiago-García, B.; Noguera-Julián, A.; Lanaspa, M.; Lancell, L.; Calo Carducci, F.I.; Gabrovská, N.; Velizarova, S.; Prunk, P.; Osterman, V., et al. COVID-19 in children and adolescents in Europe: A multinational, multicentre cohort study. Lancet Child. Adolesc. Health 2020, 4, 653–661. [CrossRef]

33. Fraile Navarro, D.; Tendale, B.; Tingay, D.; Vasilunasa, N.; Anderson, L.; Best, J.; Burns, P.; Cheyne, S.; Craig, S.S.; Erickson, S.J., et al. Clinical care of children and adolescents with COVID-19: Recommendations from the National COVID-19 Clinical Evidence Taskforce. Med. J. Aust. 2021. [CrossRef]

34. Shekerdemian, L.S.; Mahmood, N.R.; Wolfe, K.K.; Riggs, B.J.; Ross, C.E.; McKiernan, C.A.; Heidemann, S.M.; Kleinman, L.C., et al. Difficult Intubation Collaborative and the Canadian Pediatric Anesthesia Society. Critical coronavirus and kids epidemiology cake study. Pediatric Critical Care and COVID-19. Pediatrics 2021, e20201766. [CrossRef]

35. González-Dambrauskas, S.; Vásquez-Hoyos, P.; Camporesi, A.; Díaz-Rubio, F.; Piñeres-Olave, B.E.; Fernández-Sarmiento, J.; Gertz, S.; Harwayne-Gidansky, I.; Pietroboni, P.; Shein, S.L., et al. Critical coronavirus and kids epidemiology cake study. Critical Care of Children and Adolescents with COVID-19: Recommendations from the National COVID-19 Clinical Evidence Taskforce. Postgrad. Med. J. 2021, 97, 34–39. [CrossRef]

36. Bui, T.; Skřatušková, M.; Morin, L.; Carducci, F.I.; Gabrovská, N.; Velizarova, S.; Ošlejšková, O.; Ošlejšková, O.; Lauer, S.A.; Alhazzani, W.; Agus, M.S.D.; Flori, H.R.; Inwald, D.P.; Nadel, S.; Schlabach, L.J.; Tasker, R.C.; Argent, A.C., et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020, 46, 10–67. [CrossRef]
46. Davis, A.L.; Carcillo, J.A.; Aneja, R.K.; Deymann, A.J.; Lin, J.C.; Nguyen, T.C.; Okhuysen-Cawley, R.S.; Relvas, M.S.; Rozenfeld, R.A.; Skippen, P.W.; et al. American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. Crit. Care Med. 2017, 45, 1061–1093. [CrossRef]

47. Harris, J.; Ramelet, A.S.; van Dijk, M.; Pokorna, P.; Wielen, J.; Tume, L.; Tibboel, D.; Ista, E. Clinical recommendations for pain, sedation, withdrawal and delirium assessment in critically ill infants and children: An ESPNIC position statement for healthcare professionals. Intensive Care Med. 2016, 42, 972–986. [CrossRef]

48. Walker, T.; Kudchadkar, S.R. Pain and Sedation Management: 2018 Update for the Rogers' Textbook of Pediatric Intensive Care. Pediatr. Crit. Care Med. 2019, 20, 54–61. [CrossRef]

49. Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Veklury (Remdesivir) for Hospitalized Pediatric Patients Weighing 35 kg to Less than 40 kg or Hospitalized Pediatric Patients Less Than 12 Years of Age Weighing at Least 3.5 kg. Available online: https://www.fda.gov/media/137566/download (accessed on 5 February 2022).

50. Horby, P.; Lim, W.S.; Emberson, J.R.; Mathun, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; et al. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2021, 384, 693–704. [CrossRef] [PubMed]

51. Gordon, A.C.; Mouncey, P.R.; Al-Beidh, F.; Rowan, A.K.; Arabi, Y.M.; Annane, D.; Beane, A.; van Bentum-Puijk, W.; Berry, L.R.; et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N. Engl. J. Med. 2021, 384, 1491–1502. [CrossRef] [PubMed]

52. Henderson, L.A.; Canna, S.W.; Friedman, K.G.; Gorelik, M.; Lapidus, S.K.; Bassiri, H.; Behrens, E.M.; Ferris, A.; Kernan, K.F.; Schulte, G.S.; et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021, 73, e13–e29. [CrossRef] [PubMed]

53. Hoang, A.; Chorath, K.; Moreira, A.; Evans, M.; Burmeister-Morton, F.; Burmeister, F.; Naqvi, R.; Petershack, M.; Moreira, A. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine 2020, 24, 100433. [CrossRef] [PubMed]

54. Tan, W.; Aboulhosn, J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int. J. Cardiol. 2020, 309, 70–77. [CrossRef] [PubMed]

55. Cheung, E.W.; Zachariah, P.; Gorelik, M.; Boneparth, A.; Kernie, S.G.; Orange, J.S.; Milner, J.D. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. JAMA 2020, 324, 294–296. [CrossRef] [PubMed]

56. Harwood, R.; Allin, B.; Jones, C.E.; Whittaker, E.; Ramnarayan, P.; Ramanan, A.V.; Kaleem, M.; Tulloh, R.; Peters, M.J.; Almond, S.; et al. Multisystem inflammatory syndrome (MIS-C) following COVID-19 dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Vaccine 2020, 38, 2966–2972. [CrossRef] [PubMed]

57. Feldstein, L.R.; Rose, E.B.; Horwitz, S.M.; Collins, J.P.; Newhams, M.M.; Son, M.B.F.; Newburger, J.W.; Kleinman, L.C.; Heidemann, S.M.; et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV-2 challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 2020, 38, 7497–7504. [CrossRef] [PubMed]

58. Dufort, E.M.; Koumans, E.H.; Chow, E.J.; Rosenthal, E.M.; Muse, A.; Rowlands, J.; Barranco, M.A.; Maxted, A.M.; Rosenberg, E.S.; Easton, D.; et al. Multisystem Inflammatory Syndrome in Children. N. Engl. J. Med. 2020, 383, 347–358. [CrossRef] [PubMed]

59. Godfred-Cato, S.; Bryant, B.; Leung, J.; Oster, M.E.; Conklin, L.; Abrams, J.; Roguski, K.; Wallace, B.; Prezzato, E.; Koumans, E.H.; et al. COVID-19-associated Multisystem Inflammatory Syndrome in Children United States, March-July 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1074–1080. [CrossRef]

60. Kam, Y.W.; Kien, F.; Roberts, A.; Cheung, Y.C.; Lamirande, A.W.; Vogel, L.; Chu, S.L.; Tse, J.; Guerner, J.; Zaki, S.R.; et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV-2 challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 2020, 38, 7497–7504. [CrossRef] [PubMed]

61. Wang, S.F.; Tseng, S.P.; Yen, C.H.; Yang, T.Y.; Tsao, C.H.; Chen, C.W.; Chen, K.H.; Liu, F.T.; Liu, W.T.; Chen, Y.M.; et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem. Biophys. Res. Commun. 2014, 451, 208–214. [CrossRef] [PubMed]

62. Morris, S.B.; Schwartz, N.G.; Patel, P.; Abbo, L.; Beauchamps, L.; Balan, S.; Lee, E.H.; Paneth-Pollak, R.; Geeveraghese, A.; Lash, M.K.; et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection-United Kingdom and United States, March-August 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1450–1456. [CrossRef] [PubMed]

63. Carlin, R.F.; Fischer, A.M.; Pitkowsky, Z.; Abel, D.; Sewell, T.B.; Landau, E.G.; Caddle, S.; Robbins-Milne, L.; Boneparth, A.; Milner, J.D.; et al. Discriminating Multisystem Inflammatory Syndrome in Children Requiring Treatment from Common Febrile Conditions in Outpatient Settings. Crit. Care Med. 2021, 49, 229–236. [CrossRef] [PubMed]

64. McCrindle, B.W.; Rowley, A.H.; Newburger, J.W.; Burns, J.C.; Bolger, A.E.; Gewitz, M.; Baker, A.L.; Jackson, M.A.; Takahashi, M.; Shah, P.B.; et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation 2017, 135, e927–e999. [CrossRef] [PubMed]

65. Ouldali, N.; Toubiana, J.; Antona, D.; Javouhey, E.; Madhi, F.; Lorrot, M.; Léger, P.L.; Galeotti, C.; Claude, C.; Wiedemann, A.; et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone with Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA 2021, 325, 855–864. [CrossRef] [PubMed]
66. Cattalini, M.; Taddio, A.; Bracaglia, C.; Cimaz, R.; Paolera, S.D.; Filocamo, G.; La Torre, F.; Lattanzi, B.; Marchesi, A.; Simonini, G.; et al. Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): A diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. *Ital. J. Pediatr.* 2021, 47, 24. [CrossRef]

67. Wardle, A.J.; Connolly, G.M.; Seager, M.J.; Tulloh, R.M. Corticosteroids for the treatment of Kawasaki disease in children. *Cochrane Database Syst. Rev.* 2017, 1, CD011188. [CrossRef]

68. Belhadjer, Z.; Méot, M.; Bajolle, F.; Khraiche, D.; Legendre, A.; Abakka, S.; Auriau, J.; Grimaud, M.; Oualha, M.; Beghetti, M.; et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. *Circulation* 2020, 142, 429–436. [CrossRef]

69. Bansal, N.; Azeka, E.; Neunert, C.; Kim, J.S.; Murray, J.; Kirk, C.; Lorts, A.; Rosenthal, D.; VanderPluym, C. Multisystem Inflammatory Syndrome Associated with COVID-19 Anti-thrombosis Guideline of Care for Children by Action. *Pediatr. Cardiol.* 2021, 42, 1635–1639. [CrossRef]

70. Prata-Barbosa, A.; Lima-Setta, F.; Santos, G.R.D.; Lanzioitti, V.S.; de Castro, R.E.V.; de Souza, D.C.; Raymundo, C.E.; de Oliveira, F.R.C.; de Lima, L.F.P.; Tonal, C.T.; et al. Pediatric patients with COVID-19 admitted to intensive care units in Brazil: A prospective multicenter study. *J. Pediatr.* 2020, 96, 582–592. [CrossRef] [PubMed]

71. Kompaniyets, L.; Agathis, N.T.; Nelson, J.M.; Preston, L.E.; Ko, J.Y.; Belay, B.; Pennington, A.F.; Danielson, M.L.; DeSisto, C.L.; Chevinsky, J.R.; et al. Underlying Medical Conditions Associated with Severe COVID-19 Illness Among Children. *JAMA Netw. Open* 2021, 4, e2111182. [CrossRef] [PubMed]

72. Bailey, L.C.; Razzaghi, H.; Burrows, E.K.; Bunnell, H.T.; Camacho, P.E.F.; Christakis, D.A.; Eckrich, D.; Kitzmiller, M.; Lin, S.M.; Magnusen, B.C.; et al. Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States. *JAMA Pediatr.* 2021, 175, 176–184. [CrossRef] [PubMed]

73. Martin, B.; DeWitt, P.E.; Russell, S.; Anand, A.; Bradwell, K.R.; Bremer, C.; Gabriel, D.; Girvin, A.T.; Hajagos, J.G.; McMurry, J.A.; et al. Children with SARS-CoV-2 in the National COVID Cohort Collaborative (N3C). *medRxiv Prepr.* 2021. [CrossRef]